{"title": "FDA | Biologics Effectiveness and Safety (BEST)", "author": null, "url": "https://bestinitiative.org/vaccines-and-allergenics", "hostname": "bestinitiative.org", "description": null, "sitename": "bestinitiative.org", "date": "2023-07-20", "cleaned_text": "Vaccines & Allergenics The Center for Biologics Evaluation and Research (CBER) regulates vaccine products. Many of these are childhood vaccines that have contributed to a significant reduction of vaccine-preventable diseases. CBER regulates allergenic products. There are currently three types of allergenic products licensed for use: allergen extracts, allergen patch tests, and antigen skin tests. Most Recent Vaccines & Allergenics Assessments Title Date FDA Evaluation of a Preliminary Seizure Safety Signal from Rapid Surveillance of Children Ages 2 - 4/5 yrs. following COVID-19 mRNA Vaccination 07/20/2023 (Pfizer BioNTech), mRNA-1273 (Moderna) Master Protocol: Assessment of the Risk of Adverse Events Following Influenza Vaccinations Approved during the 2022-2023 Influenza Season 06/22/2023 Vaccines, flu shot, immunization, influenza, flu, adverse events, AE Safety Surveillance of Vaccines Used for Mpox Prevention: Active Monitoring Master Protocol [ Mpox-Vax-Safety-Monitoring-Protocol-2022](https://bestinitiative.org/wp-content/uploads/2023/01/Mpox-Vax-Safety-Monitoring-Protocol-2022.pdf) [Mpox-Vax-Safety-Monitoring-Protocol-Addendum Jun 2023 (pdf)](https://bestinitiative.org/wp-content/uploads/2023/06/Mpox-Vax-Safety-Monitoring-Protocol-Addendum-Jun-2023.pdf) [Mpox-Vax-Safety-Monitoring-Protocol-All Files (zip)](https://bestinitiative.org/wp-content/uploads/2023/06/Mpox-Vax-Safety-Monitoring-Protocol-All_Files.zip) Show more + The Safety Surveillance of Vaccines Used for Mpox Prevention: Active Monitoring Master Protocol was finalized on 12/16/2022. An addendum for this protocol was added on 6/19/2023. 06/19/2023 Monkey pox, Mpox, Smallpox vaccine, stockpile vaccine, vaccination COVID-19 Vaccine Safety Surveillance: Active Monitoring Master Protocol + The COVID-19 Vaccine Safety Surveillance: Active Monitoring Master Protocol was finalized 2/10/2021. An addendum for this protocol for the pediatric population was added 4/12/2022 and updated on 12/12/2022. An addendum for this protocol for following third or booster dose administration among a commercially insured population aged 18-64 years and the Medicare population aged 65 years and older was added 5/27/2022. An addendum to this protocol for bivalent vaccine administration in the commercially insured population aged 6 months and older was added 12/23/2022. An addendum to describe the low uptake and discontinuation of near-real time surveillance of Novavax (NVX-CoV2373) COVID-19 vaccine (recombinant, adjuvanted) among the adult population ages 18 years and older was added 3/09/2023. 03/09/2023 COVID-19, Safety, Surveillance, Active Monitoring, Vaccines, Pediatric, Bivalent Booster, Vaccine safety, NVX-CoV2373, Pharmacovigilance Assessment of Stroke Following COVID-19 mRNA, Bivalent Booster Vaccination 02/27/2023 Evaluating the Risk of Adverse Events After COVID-19 Diagnosis 02/10/2023 coronavirus disease 2019, VAERS, hazard ratio, risk ratio Risk of Adverse Events of Special Interest Post COVID-19 Vaccines: A Real-World Study Across University of California Health System 01/21/2023 Vaccine, COVID-19, messenger RNA (mRNA), BNT162b2 (Pfizer BioNTech), mRNA-1273 (Moderna), University of California Safety Assessment of 3rd Dose/Booster of COVID-19 mRNA Vaccines 08/31/2022 booster dose, 3rd dose, safety assessment, covid-19 mrna Assessment of Effectiveness of COVID-19 Vaccination in the United States Protocol [ C19-VX-Effectiveness-Protocol 2022 508](https://bestinitiative.org/wp-content/uploads/2022/03/C19-VX-Effectiveness-Protocol_2022_508.pdf) (pdf) Show more + The Assessment of Effectiveness of COVID-19 Vaccination in the United States Protocol was finalized 3/3/2022. An addendum for this protocol for the pediatric population was added 8/18/2022. 08/18/2022 COVID-19, Vaccine, Effectiveness, Comparative, Analysis Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring [ Events of Special Interest for COVID-19 Vaccine Safety Monitoring-All Files (zip)](https://bestinitiative.org/wp-content/uploads/2022/08/Background-Rates-of-Adverse-Events-of-Special-Interest_for_COVID-19_Vaccine_Safety_Monitoring-All_Files.zip) Show more + The \"Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring\" Protocol was finalized 1/12/21. An addendum and final report for this protocol were added December 2021. An addendum for CVS Health Database Results was added to this protocol on 7/28/22. 07/28/2022 COVID-19, Safety, Surveillance, Active, Monitoring, AESI, Background Rates Supplementing Administrative Claims COVID-19 Vaccine Data with Immunization Information Systems (IIS) Data: A Feasibility Study Report 07/26/2022 Immunization, Information, Systems, Administrative, Claims BETTER: Bayesian Evaluation of Time-To-Event and Reliability (for vaccine surveillance) 07/22/2022 Bayesian, Vaccines, Surveillance, Time-to-event, Reliability, Research Protocol COVID-19 Vaccine Safety Surveillance Project: Comparative Risk of Myocarditis or Pericarditis following COVID-19 mRNA Vaccination [ C-19-MyoPericarditis-mRNA-Comparative-Safety-Protocol-2021](https://bestinitiative.org/wp-content/uploads/2021/12/C-19-MyoPericarditis-mRNA-Comparative-Safety-Protocol-2021.pdf) (pdf) 12/10/2021 COVID-19, Safety, Surveillance, Active, Monitoring, Myocarditis, Pericarditis of Acute Myocardial Infarction, Pulmonary Embolism, Disseminated Intravascular Coagulation and Immune Thrombocytopenia Following COVID-19 Vaccination Protocol [ C-19-Vaccine-Safety-AMI-PE-DIC-ITP-Protocol-2021](https://bestinitiative.org/wp-content/uploads/2021/09/C-19-Vaccine-Safety-AMI-PE-DIC-ITP-Protocol-2021.pdf) (pdf) A public communication for this protocol is available at [https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/initial-results-near-real-time-safety-monitoring-covid-19-vaccines-persons-aged-65-years-and-older](https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/initial-results-near-real-time-safety-monitoring-covid-19-vaccines-persons-aged-65-years-and-older). 07/30/2021 COVID-19, Acute Myocardial Infarction, Pulmonary Embolism, Disseminated Intravascular Coagulation, Immune Thrombocytopenia Assessment of Risk of Safety Outcomes Following COVID-19 Vaccination Draft Master Protocol [ COVID-19-Vaccine-Safety-Inferential-Master-Protocol-Final-2021](https://bestinitiative.org/wp-content/uploads/2021/08/COVID-19-Vaccine-Safety-Inferential-Master-Protocol-Final-2021.pdf) (pdf) 05/28/2021 COVID-19, Safety Outcomes Assessment of the Performance of COVID-19 Diagnosis Code Using SARS-CoV-2 Test Results Draft Protocol [ Assessment-of-C19-Diagnosis-Code-Using-SARS-CoV-2-Test-Results-Study-Draft-Protocol](https://bestinitiative.org/wp-content/uploads/2021/04/Assessment-of-C19-Diagnosis-Code-Using-SARS-CoV-2-Test-Results-Study-Draft-Protocol.pdf) (pdf) 04/08/2021 COVID-19, Diagnosis Code, Test Results Adherence to Administration Schedules of U.S.-Licensed Rotavirus Vaccines for Infants, 2014-2018 [ Adherence Rotavirus Vaccines Infants Specifications 2020](https://bestinitiative.org/wp-content/uploads/2020/08/Adherence_Rotavirus_Vaccines_Infants_Specifications_2020-1.pdf) Rotarix, immunization Final Report: Validating Pregnancy Outcomes and Gestational Age in Claims-EMR Linked Database [ Validating Pregnancy Outcomes Linked Database Report 2020](https://bestinitiative.org/wp-content/uploads/2020/08/Validating_Pregnancy_Outcomes_Linked_Database_Report_2020-1.pdf) (pdf) 06/2020 Pregnancy Outcomes, Algorithm Validation, Gestational Age, Claims, EMR, Linked Database, ICD-10-CM, GAIA, Global Alignment of Immunization safety Assessment, Claims-based algorithm Study Protocol: Validating Pregnancy Outcomes and Gestational Age in a Claims-EMR Linked Database [ Validating Pregnancy Outcomes Linked Database Protocol 2020](https://bestinitiative.org/wp-content/uploads/2020/08/Validating_Pregnancy_Outcomes_Linked_Database_Protocol_2020-1.pdf) (pdf) [Validating Pregnancy Outcomes Linked Database D1 Protocol 2020 (xlsx)](https://bestinitiative.org/wp-content/uploads/2020/08/Validating-Pregnancy-Outcomes-Linked-Database_D1_Protocol_2020-1.xlsx) [Validating Pregnancy Outcomes Linked Database D2 Protocol 2020 (xlsx)](https://bestinitiative.org/wp-content/uploads/2020/08/Validating-Pregnancy-Outcomes-Linked-Database_D2_Protocol_2020-1.xlsx) [Validating Pregnancy Outcomes Linked Database D3 Protocol 2020 (xlsx)](https://bestinitiative.org/wp-content/uploads/2020/08/Validating-Pregnancy-Outcomes-Linked-Database_D3_Protocol_2020-1.xlsx) [Validating Pregnancy Outcomes Linked Database D4 Protocol 2020 (xlsx)](https://bestinitiative.org/wp-content/uploads/2020/08/Validating-Pregnancy-Outcomes-Linked-Database_D4_Protocol_2020-1.xlsx) [Validating Pregnancy Outcomes Linked Database D5 Protocol 2020 (xlsx)](https://bestinitiative.org/wp-content/uploads/2020/08/Validating-Pregnancy-Outcomes-Linked-Database_D5_Protocol_2020-1.xlsx) [Validating Pregnancy Outcomes Linked Database Protocol 2020 All Files (zip)](https://bestinitiative.org/wp-content/uploads/2020/08/Validating_Pregnancy_Outcomes_Linked_Database_Protocol_2020_All_Files-1.zip) Show more + 06/2020 Pregnancy Outcomes, Algorithm Validation, Gestational Age, Claims, EMR, Linked Database, ICD-10-CM, GAIA, Global Alignment of "}